Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06527365
PHASE2

Safety and Efficacy of VDPHL01 in Males and Females With AGA

Sponsor: Veradermics, Inc.

View on ClinicalTrials.gov

Summary

This study will evaluate the safety and efficacy of VDPHL01 in male and female subjects with Androgenetic Alopecia (AGA). AGA (or pattern of hair loss) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablets for males and VDPHL01 4.5 mg Tablets for females are an investigational oral drug to treat male and female pattern baldness. This multiple center, open-label, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13). Male subjects that meet the study eligibility criteria will be administered VDPHL01 once daily for 12 months. Female subjects that meet the study eligibility criteria will be administered VDPHL01 either once or twice daily for 12 months.

Official title: An Open-Label Multi-Dose Study to Evaluate the Safety and Efficacy of VDPHL01 in Male and Female Subjects With Androgenetic Alopecia

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

70

Start Date

2024-07-08

Completion Date

2026-08

Last Updated

2025-11-06

Healthy Volunteers

No

Interventions

DRUG

VDPHL01

VDPHL01 Extended Release (ER) Tablet

Locations (4)

01

San Diego, California, United States

04

New Albany, Indiana, United States

03

Hackensack, New Jersey, United States

02

South Jordan, Utah, United States